Effect of MEMOPTIC on Visual Field of Patients Followed for a Chronic Open-angle Glaucoma

• Status: Recruiting
• Trial end date: 2022-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Open-angle glaucoma is a degeneration of the optic nerve, highlighted by campimetric alterations, and wose only current therapeutic target is the lowering of the intra-ocular pressure (using eye drops, surgery or laser). MEMOPTIC is a tablet combining citicoline, magnesium and Gingko biloba, which have a neuroprotective effect already used in neurodegenerative diseases such as Alzheimer's disease for example. Citicoline has also shown several promising results in ophthalmological diseases (glaucoma, amblyopia or more recently in ischemic optic neuropathies). The citicoline used in eye drops (NEURODROP) has already shown results on the preservation of the vision of glaucomatous patients.

The purpose of this project is to determine if MEMOPTIC can have an effect, in addition to the conventional treatments, in the preservation of vision of patients treated for an open-angle glaucoma.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire, Amiens

Criteria

Inclusion Criteria:

• diagnosis of GCAO defined by OCT RNFL alterations and visual fields defects

• age between 20 and 80 years old

• Well controled intra-ocular pressure under treatment (PIO<21mmHg or decreased by 20% compared to initial the PIO)

Exclusion Criteria:

• retinal or macular disease

• diagnosis of cataract or surgery of cataract during the follow-up

• allergy to citicolin

• ocular hypertonia due to a secondary cause (like corticosteroids)

• history of anterior, intermediate or posterior uveitis

• general treatment affecting PIO (beta blockers, corticosteroids)

• pregnancy or breastfeeding